BioSpace News Archive

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced initial data from its ongoing Phase 1 study of tidutamab (XmAb ® 18087), an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs). The data were presented at the North American Neuroendocrine Tumor Society’s 2020 Mu

Yesterday, Health Canada received its first submission for authorization of a COVID-19 vaccine developed by AstraZeneca in partnership with the University of Oxford . This is an important step for Canada in its response to the pandemic, but it is just one step on the road to obtaining safe and effective vaccines. Health Canada will be d

Haematologic Technologies (HTI), a leading protein chemistry company providing products and analytical services supporting the research, development, and commercialization of large molecule biotherapeutics, today

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adults with malignant pleural mesothelioma that cannot be re

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 11 newly-hired employees options to purchase an aggregate of 84,000 shares of Akebia’s common stock on September 30, 2020, as inducements material to each such employee’s entering into employment with Akebia.

Unum Group (NYSE: UNM) will release its third quarter 2020 results October 27 , at approximately 4:15 p.m. Eastern time . The earnings release and financial supplement will be available in the Investors section of the company’s website , which can be directly accessed at www.investors.unum.com . Members of Unum Group se

BD announced that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020, at 8:00 a.m. BD will issue a press release detailing the quarter’s earnings earlier that morning..

Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Company’s common stock with an exercise price of $17.29 per share, the closing price of Assembly’s common stock on October 1, 2020.

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) + Yervoy ® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA in this setting 1,2 Approval is based on CheckMate -743 in which Opdivo + Yervoy demonstrated superior overall survival vs. standard of care chemot

Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients who have had a complete surgical